Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07551635 · ClinicalTrials.gov registry record · Phase 2
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07551635 is a Phase 2 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT07551635, a Phase 2 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once daily in 21-day cycles. The primary objective is to assess the objective response rate of FHD-286 in this population. The names of the study drug involved in this study is: • FHD-286 (a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor targeting the SWI/SNF chromatin remodeling complex (also known as the BAF complex)
Interventions
- DRUG FHD-286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-09-04 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07551635
The ClinicalTrials.gov registry entry for NCT07551635 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FHD-286 is the first listed.
NCT07551635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07551635 about?
NCT07551635 is a clinical study titled "SMARCA4/2 Inhibitor for POU2F3-Positive SCLC". This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once dai...
What is the current status of trial NCT07551635?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-09-04. Estimated completion is 2029-01-31.
What interventions are being tested in trial NCT07551635?
The interventions under investigation include: FHD-286 (DRUG).
Who is sponsoring clinical trial NCT07551635?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.